109 related articles for article (PubMed ID: 38299402)
1. Clinical Significance of HHLA2 as a Novel Therapeutic Target for Colorectal Cancer.
Wang H; An Z; Liu Y; Ding G; Deng G; Ji C; Gong Y
Curr Cancer Drug Targets; 2024 Jan; ():. PubMed ID: 38299402
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of HHLA2 and CD8 Immunohistochemical Expression in Colorectal Carcinoma and Their Prognostic Significance.
Gawesh ZM; Ibrahim EM; ElKalla HMHR; Awad AAH; Mohamed MA
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4309-4319. PubMed ID: 38156868
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma.
Zhu Z; Dong W
Onco Targets Ther; 2018; 11():1563-1570. PubMed ID: 29593422
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 is Upregulated and Independently Predicts Unfavorable Prognosis in Bladder Urothelial Carcinoma.
Lin G; Ye H; Wang J; Chen S; Chen X; Zhang C
Nephron; 2019; 141(4):256-264. PubMed ID: 30602154
[TBL] [Abstract][Full Text] [Related]
5. HHLA2 promotes tumor progression by long non‑coding RNA H19 in human gallbladder cancer.
Zhang Y; Li H; Lv C; Wu B; Yu Y; Zhong C; Lang Q; Liang Z; Li Y; Shi Y; Zhang J; Xu F; Tian Y
Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35920182
[TBL] [Abstract][Full Text] [Related]
6. HHLA2 overexpression is a novel biomarker of malignant status and poor prognosis in gastric cancer.
Wei L; Tang L; Chang H; Huo S; Li Y
Hum Cell; 2020 Jan; 33(1):116-122. PubMed ID: 31552567
[TBL] [Abstract][Full Text] [Related]
7. Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 Possesses Prognostic Significance and Promotes Progression of Papillary Thyroid Cancer.
Niu Y; Huang Y; Dong A; Sun Y
Int J Gen Med; 2022; 15():1509-1516. PubMed ID: 35210824
[TBL] [Abstract][Full Text] [Related]
8. The association of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) expression with gastric cancer prognosis.
Shimonosono M; Arigami T; Yanagita S; Matsushita D; Uchikado Y; Kijima Y; Kurahara H; Kita Y; Mori S; Sasaki K; Omoto I; Maemura K; Uenosono Y; Ishigami S; Natsugoe S
Oncotarget; 2018 Apr; 9(31):22069-22078. PubMed ID: 29774123
[TBL] [Abstract][Full Text] [Related]
9. High expression of folate cycle enzyme MTHFD1L correlates with poor prognosis and increased proliferation and migration in colorectal cancer.
He Z; Wang X; Zhang H; Liang B; Zhang J; Zhang Z; Yang Y
J Cancer; 2020; 11(14):4213-4221. PubMed ID: 32368304
[No Abstract] [Full Text] [Related]
10. NAT2 knockdown inhibits the development of colorectal cancer and its clinical significance.
Wang CL; Liu ZP; Guo L
Eur Rev Med Pharmacol Sci; 2021 May; 25(9):3460-3469. PubMed ID: 34002819
[TBL] [Abstract][Full Text] [Related]
11. HHLA2 promotes hepatoma cell proliferation, migration, and invasion via SPP1/PI3K/AKT signaling pathway.
Wang J; Yang K; Yang X; Jin T; Tian Y; Dai C; Xu F
Mol Carcinog; 2024 Jul; 63(7):1275-1287. PubMed ID: 38578157
[TBL] [Abstract][Full Text] [Related]
12. Human Endogenous Retrovirus-H Long Terminal Repeat- Associating Protein 2 (HHLA2) is a Novel Immune Checkpoint Protein in Lung Cancer which Predicts Survival.
Farrag MS; Ibrahim EM; El-Hadidy TA; Akl MF; Elsergany AR; Abdelwahab HW
Asian Pac J Cancer Prev; 2021 Jun; 22(6):1883-1889. PubMed ID: 34181347
[TBL] [Abstract][Full Text] [Related]
13. Clinical Value of Human Endogenous Retrovirus-H Long Terminal Repeat Associating 2 (HHLA2) in Small Cell Lung Cancer.
Zhang X; Qin Y; Chen X; Xiong M; Shu S
Technol Cancer Res Treat; 2024; 23():15330338241240683. PubMed ID: 38613340
[No Abstract] [Full Text] [Related]
14. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target.
Chen D; Chen W; Xu Y; Zhu M; Xiao Y; Shen Y; Zhu S; Cao C; Xu X
J Med Genet; 2019 Jan; 56(1):43-49. PubMed ID: 29967134
[TBL] [Abstract][Full Text] [Related]
15. Overexpression and Role of HHLA2, a Novel Immune Checkpoint, in Colorectal Cancer.
Kula A; Dawidowicz M; Mielcarska S; Kiczmer P; Skiba H; Krygier M; Chrabańska M; Piecuch J; Szrot M; Robotycka J; Ochman B; Strzałkowska B; Czuba Z; Świętochowska E; Waniczek D
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982953
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.
Mohamed SY; Kaf RM; Ahmed MM; Elwan A; Ashour HR; Ibrahim A
J Gastrointest Cancer; 2019 Dec; 50(4):824-837. PubMed ID: 30136202
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive value of long non-coding RNA GAS5 and mircoRNA-221 in colorectal cancer and their effects on colorectal cancer cell proliferation, migration and invasion.
Liu L; Meng T; Yang XH; Sayim P; Lei C; Jin B; Ge L; Wang HJ
Cancer Biomark; 2018; 22(2):283-299. PubMed ID: 29630521
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Basic Evaluation of the Effects of Upregulated TNFAIP3 Expression on Colorectal Cancer.
Li J; Ren S; Zhang Y; Wu B; He M; Shan Z; Liu Y; Wang Y
Dis Markers; 2022; 2022():1263530. PubMed ID: 36033828
[TBL] [Abstract][Full Text] [Related]
19. Forkhead Box S1 mediates epithelial-mesenchymal transition through the Wnt/β-catenin signaling pathway to regulate colorectal cancer progression.
Zhang L; Ren CF; Yang Z; Gong LB; Wang C; Feng M; Guan WX
J Transl Med; 2022 Jul; 20(1):327. PubMed ID: 35864528
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNA GIHCG induces cancer progression and chemoresistance and indicates poor prognosis in colorectal cancer.
Jiang X; Li Q; Zhang S; Song C; Zheng P
Onco Targets Ther; 2019; 12():1059-1070. PubMed ID: 30799935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
